Novel Mechanisms for the Antifibrotic Action of Nintedanib

Idiopathic pulmonary fibrosis (IPF) is a disease with relentless course and limited therapeutic options. Nintedanib (BIBF-1120) is a multiple tyrosine kinase inhibitor recently approved by the U.S. Food and Drug Administration for the treatment of IPF. The precise antifibrotic mechanism(s) of action...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Am J Respir Cell Mol Biol
Autori principali: Rangarajan, Sunad, Kurundkar, Ashish, Kurundkar, Deepali, Bernard, Karen, Sanders, Yan Y., Ding, Qiang, Antony, Veena B., Zhang, Jianhua, Zmijewski, Jaroslaw, Thannickal, Victor J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Thoracic Society 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742925/
https://ncbi.nlm.nih.gov/pubmed/26072676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1165/rcmb.2014-0445OC
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi